Fig. 7From: Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) databaseThe progression of cumulative incidence for the 10 most frequently reported PTsBack to article page
